Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (8042)	3/18/2003 12:02:45 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Joe, These are the same results they reported previously. As I said at the time they seemed pretty impressive to me for such a small study (only 17 patients analyzed). Getting statistical significance in a study of this size makes it likely that the effect is robust. But the world will (rightly) not be convinced until this is replicated with larger numbers. Here is what they say today: As reported in The American Journal of Geriatric Cardiology, patients who received ALT-711 for 16 weeks experienced a statistically significant reduction in left ventricular (LV) mass, in a preliminary analysis of the first 17 patients (of a total of 23) in the DIAMOND trial. LV mass was 125+36 gm at baseline and decreased to 119+35 gm at follow-up (p=0.04). DIAMOND patients also had a marked improvement in left ventricular diastolic filling (p=0.02). Additionally, the drug demonstrated a positive effect on patients' quality of life, as measured by a well-established heart failure/quality of life questionnaire (total score p=0.06; physical score p=0.053). Measurements of exercise tolerance and aortic distensibility proved to be more variable than anticipated for a study of this size and were not reportable. But this stock is still going to live or die based on the upcoming results of its big studies. Peter